/* ProTGen StoryLab — internal strategy content */

const SL_STAGES = [
  { key: "open", n: "0", t: "The story travel problem", tag: "Frame" },
  { key: "context", n: "1", t: "Shared context", tag: "Listen" },
  { key: "heard", n: "2", t: "What we heard", tag: "Listen" },
  { key: "crux", n: "3", t: "The strategic crux", tag: "Frame" },
  { key: "belief", n: "4", t: "Belief sequence", tag: "Envision" },
  { key: "audience", n: "5", t: "Audience doorways", tag: "Envision" },
  { key: "assume", n: "6", t: "Assumption ranker", tag: "Assumptions" },
  { key: "proof", n: "7", t: "Proof ladder", tag: "Assumptions" },
  { key: "xmap", n: "8", t: "Website experience map", tag: "Build" },
  { key: "empty", n: "9", t: "Empty room test", tag: "Build" },
];

const SL_QUESTIONS = [
  { id: "q1", q: "When Carter presents the current deck, where do people lean in — and where do they get stuck?", listen: "Listening for: the moments of energy vs. the moments of confusion. The stuck points become the website's hardest-working sections." },
  { id: "q2", q: "Who is the “new profile” of investor or partner you most need the story to work for?", listen: "Listening for: which of the four audiences leads — and whose skepticism we design the path of belief around." },
  { id: "q3", q: "What do you want them to believe after 90 seconds that they may not believe today?", listen: "Listening for: the single belief that must land first. It sets the hero and the deck opening." },
  { id: "q4", q: "Is ProT‑096 the hero — or the first proof point for a broader platform?", listen: "Listening for: the bridge. Too narrow and it reads as one program; too abstract and the platform floats. The article argues for ‘bridge.’" },
  { id: "q5", q: "What is the one misconception about Notch, thymic reactivation, or immune reconstitution we must overcome fast?", listen: "Listening for: the objection to pre‑empt early — the thing that, left unanswered, makes everything after it harder to hear." },
  { id: "q6", q: "Which proof points are strongest today: biology, team, manufacturing, IND path, partner validation, pipeline optionality?", listen: "Listening for: what anchors the proof ladder now vs. what stays aspirational. This governs what can lead public‑facing copy." },
  { id: "q7", q: "Where does the website already feel right — and where does it still feel incomplete?", listen: "Listening for: what to keep vs. rebuild. The direction is likely right but incomplete; this tells us where to spend effort." },
];

const SL_CRUX = [
  { id: "portable", title: "A portable‑conviction problem", desc: "The story works when Carter explains it. The crux is making it travel — understandable, credible, and retellable without him in the room.", tag: "Recommended", chosen: true },
  { id: "prettier", title: "A better‑collateral problem", desc: "The materials need to look sharper and more premium. (We believe this under‑reads the real challenge.)", tag: "Likely too narrow" },
  { id: "category", title: "A category‑definition problem", desc: "The market doesn't yet have language for immune competence restoration; the job is to name and own the category.", tag: "Part of it" },
];

const SL_BELIEFS = [
  { id: "b1", h: "Immune compromise is a major problem", p: "A major, under‑addressed clinical and strategic problem.", lead: "outcome" },
  { id: "b2", h: "Immune competence is a distinct frontier", p: "A new therapeutic category, not a variation on modulation.", lead: "category" },
  { id: "b3", h: "Targeted Notch activation is the lever", p: "A plausible leverage point for rebuilding adaptive immunity.", lead: "mechanism" },
  { id: "b4", h: "ProTGen's platform is differentiated", p: "Precise, controlled, programmable, disciplined.", lead: "platform" },
  { id: "b5", h: "ProT‑096 is the first proof point", p: "The right first clinical wedge — not the whole company.", lead: "asset" },
  { id: "b6", h: "Execution is credible", p: "CMC, manufacturing, IND, biomarkers, safety, milestones.", lead: "execution" },
  { id: "b7", h: "The opportunity deserves a conversation now", p: "Engage before the category becomes obvious.", lead: "timing" },
];

const SL_LEAD_IMPLICATION = {
  outcome: "If immune competence leads → an outcome‑first story. Hero and deck open with the human + clinical consequence, then earn the mechanism. Best for category investors and champions.",
  category: "If the category frame leads → a white‑space story. Open by naming the frontier, then anchor it in ProT‑096. Strong for category‑creation investors; risk of feeling abstract to clinical‑transition investors.",
  mechanism: "If targeted Notch leads → a mechanism‑first story. Risks sounding like ‘a Notch company.’ Use only with scientific evaluators who want the biology up front.",
  platform: "If platform leads → a capability story. Powerful for BD option value, but can read as ‘too broad, too early’ without the first wedge close behind.",
  asset: "If ProT‑096 leads → an asset‑first story. Concrete and de‑risking for clinical‑transition investors; risks shrinking the company to a single program for category investors.",
  execution: "If execution leads → a de‑risking story. Reassuring for clinical‑transition diligence, but skips the ‘why this matters’ that creates conviction.",
  timing: "If ‘why now’ leads → an urgency story. Rarely strong as an opener; works best as the closing argument before the CTA.",
};

const SL_LENS = {
  Champion: { word: "Portable", h: "The internal champion", need: "Carry the story into committee or a BD meeting — and have it survive the handoff.",
    show: ["Portable one‑sentence explanation", "Downloadable one‑pager", "Proof stack + objection language", "Belief sequence in order"], cta: "Get the one‑pager", first90: "Restore immune competence. ProT‑096 is the first proof point." },
  Clinical: { word: "Executable", h: "The clinical‑transition investor", need: "Decide whether ProTGen is moving from promise to an executable clinical program.",
    show: ["ProT‑096 development path", "CMC / manufacturing credibility", "IND path + risk sequence", "Value‑inflection milestones"], cta: "Request diligence briefing", first90: "A focused first wedge with a manufacturing strategy and milestones." },
  Category: { word: "Competence", h: "The category‑creation investor", need: "Decide whether ProTGen can define a new therapeutic category.",
    show: ["Category reframe + white space", "Platform potential + discipline", "Why now", "Expansion horizons as option value"], cta: "Request investor briefing", first90: "A new category — immune competence — with a focused first wedge." },
  Partner: { word: "Option", h: "The strategic BD partner", need: "Understand where ProTGen fits in a future portfolio before the category is obvious.",
    show: ["Platform adjacency map", "Portfolio‑fit logic", "Collaboration / option paths", "ProT‑096 as proof point"], cta: "Contact partnering", first90: "An option on immune reconstitution before the category gets crowded." },
};

const SL_ASSUMPTIONS = [
  { id: "a1", h: "“Restore immune competence” is the strongest category frame", cf: "Counterfactual: investors anchor on ‘cell therapy’ or ‘Notch company’ regardless.", consequence: 5, uncertainty: 3, testCost: 2, status: "unknown" },
  { id: "a2", h: "ProT‑096 should be framed as first proof point, not the whole company", cf: "Counterfactual: an asset‑first story converts clinical‑transition investors faster.", consequence: 4, uncertainty: 3, testCost: 2, status: "unknown" },
  { id: "a3", h: "The new investor/partner profile is specific enough to design for", cf: "Counterfactual: the four segments blur into one generic audience.", consequence: 4, uncertainty: 4, testCost: 3, status: "unknown" },
  { id: "a4", h: "The Cellares / manufacturing / IND path is a credible de‑risking proof", cf: "Counterfactual: investors read it as early and discount it.", consequence: 5, uncertainty: 2, testCost: 2, status: "validated" },
  { id: "a5", h: "The current website direction is directionally right but incomplete", cf: "Counterfactual: the direction needs a fundamental reframe, not completion.", consequence: 3, uncertainty: 2, testCost: 1, status: "unknown" },
  { id: "a6", h: "The story can travel without Carter in the room", cf: "Counterfactual: belief collapses without the founder narrating it.", consequence: 5, uncertainty: 4, testCost: 2, status: "unknown" },
];

const SL_PROOF = [
  { claim: "Restore immune competence", proof: "Strategy briefs; clear category language. Patient + clinical consequence is real.", strength: "directional", where: "Homepage, deck", open: "Independent validation of category demand." },
  { claim: "Targeted Notch activation", proof: "Proprietary platform; pathway made targetable in vivo & ex vivo.", strength: "directional", where: "Platform page", open: "Public‑safe depth of mechanism data." },
  { claim: "ProT‑096 as first proof point", proof: "Defined modality, indication, and development logic.", strength: "emerging", where: "ProT‑096 page", open: "Preclinical data disclosure status." },
  { claim: "CMC / manufacturing readiness", proof: "Cellares partnership: automated manufacturing, QC, IND support.", strength: "strong", where: "Homepage, ProT‑096", open: "Timeline specificity." },
  { claim: "IND path", proof: "Regulatory support underway toward IND submission.", strength: "emerging", where: "Investors, ProT‑096", open: "Target submission window." },
  { claim: "Platform upside", proof: "Named horizons: oncology → regenerative → immune aging.", strength: "aspirational", where: "Platform page", open: "Kept as option value, not a lead claim." },
  { claim: "Partnering value", proof: "Adjacency logic across portfolio areas.", strength: "directional", where: "Investors page", open: "Specific partner fit examples." },
];

const SL_XMAP = [
  { id: "hero", n: "Hero", t: "Restore immune competence", phase: "MVP", purpose: "Establish category and action in one line.", copy: "Restore immune competence. Targeted Notch activators to rebuild durable, adaptive immune protection.", proof: "Category language; one‑sentence explanation.", risk: "If unclear, the visitor never forms the category frame." },
  { id: "problem", n: "Problem", t: "The reframe", phase: "MVP", purpose: "Challenge the current model.", copy: "Medicine attacks disease well; it rebuilds immunity poorly.", proof: "Human + clinical consequence.", risk: "Sentimentality, or leading with mechanism." },
  { id: "category", n: "Category", t: "White space", phase: "MVP", purpose: "Create the white space.", copy: "Immune competence restoration is a distinct frontier.", proof: "Old frame → gap → new frame map.", risk: "Feels abstract without the patient consequence." },
  { id: "belief", n: "Belief", t: "Seven beliefs", phase: "MVP", purpose: "Make the sequence visible and retellable.", copy: "Seven beliefs that make the story travel.", proof: "The belief sequence itself.", risk: "Too many beliefs at once overwhelms." },
  { id: "platform", n: "Platform", t: "Mechanism", phase: "MVP", purpose: "Explain why this biology.", copy: "Targeted Notch activation — made targetable.", proof: "Simplified, accurate mechanism diagram.", risk: "Too much science too early." },
  { id: "program", n: "ProT‑096", t: "Lead program", phase: "MVP", purpose: "Anchor in the first product.", copy: "ProT‑096 is the first focused proof point.", proof: "Patient context, approach, stage.", risk: "Reads as the whole company." },
  { id: "proof", n: "Proof path", t: "Milestone bridge", phase: "MVP", purpose: "Build clinical‑transition confidence.", copy: "What's de‑risked, in progress, and next.", proof: "Milestone bridge; CMC; IND.", risk: "Overclaiming stage or outcomes." },
  { id: "doorways", n: "Doorways", t: "Audience routing", phase: "MVP", purpose: "Give each audience a door in.", copy: "One story, four doors in.", proof: "Segment‑specific CTAs.", risk: "Generic, one‑size CTA." },
  { id: "cta", n: "CTA", t: "Convert", phase: "MVP", purpose: "Route to the right next step.", copy: "Request briefing / partnering / one‑pager.", proof: "Specific, circumstance‑based CTAs.", risk: "Vague ‘contact us’ leakage." },
];

Object.assign(window, { SL_STAGES, SL_QUESTIONS, SL_CRUX, SL_BELIEFS, SL_LEAD_IMPLICATION, SL_LENS, SL_ASSUMPTIONS, SL_PROOF, SL_XMAP });